Insulet Co. (PODD) Receives Consensus Rating of “Buy” from Analysts

Insulet Co. (NASDAQ:PODD) has received a consensus recommendation of “Buy” from the twenty research firms that are presently covering the stock, MarketBeat reports. Eight analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $64.42.

Several brokerages have commented on PODD. BidaskClub raised Insulet from a “sell” rating to a “hold” rating in a research report on Friday, January 26th. Zacks Investment Research raised Insulet from a “sell” rating to a “hold” rating in a research report on Thursday, February 1st. Robert W. Baird lifted their price target on Insulet from $65.00 to $72.00 and gave the stock an “outperform” rating in a research report on Friday, November 3rd. Barclays lifted their price target on Insulet from $70.00 to $75.00 and gave the stock an “overweight” rating in a research report on Monday, November 20th. Finally, Jefferies Group lifted their price target on Insulet from $58.00 to $67.00 and gave the stock a “buy” rating in a research report on Friday, November 3rd.

Shares of Insulet (NASDAQ PODD) traded down $1.01 during midday trading on Tuesday, reaching $72.46. The company’s stock had a trading volume of 466,611 shares, compared to its average volume of 537,257. The company has a current ratio of 4.88, a quick ratio of 4.42 and a debt-to-equity ratio of 4.65. The company has a market cap of $4,233.16, a P/E ratio of -144.92 and a beta of 1.59. Insulet has a 52 week low of $38.43 and a 52 week high of $78.65.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Frontier Capital Management Co. LLC increased its position in shares of Insulet by 42.4% during the fourth quarter. Frontier Capital Management Co. LLC now owns 2,096,131 shares of the medical instruments supplier’s stock valued at $144,633,000 after purchasing an additional 624,465 shares during the period. State Street Corp boosted its stake in Insulet by 7.7% in the 2nd quarter. State Street Corp now owns 1,189,155 shares of the medical instruments supplier’s stock valued at $61,014,000 after buying an additional 85,280 shares in the last quarter. Lord Abbett & CO. LLC boosted its stake in Insulet by 29.6% in the 2nd quarter. Lord Abbett & CO. LLC now owns 838,302 shares of the medical instruments supplier’s stock valued at $43,013,000 after buying an additional 191,217 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Insulet by 328.2% in the 4th quarter. Renaissance Technologies LLC now owns 661,200 shares of the medical instruments supplier’s stock valued at $45,623,000 after buying an additional 506,800 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Insulet by 104.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 611,595 shares of the medical instruments supplier’s stock valued at $34,035,000 after buying an additional 313,093 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/02/13/insulet-co-podd-receives-consensus-rating-of-buy-from-analysts.html.

About Insulet

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply